Figure: LUME-Meso: PFS with nintedanib or placebo in addition to standard chemotherapy in patients with malignant pleural mesothelioma
18.01.2017 | Onkologie | Online-Artikel
18.01.2017 | Onkologie | Online-Artikel
Figure: LUME-Meso: PFS with nintedanib or placebo in addition to standard chemotherapy in patients with malignant pleural mesothelioma